Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Total Current Liabilities (2016 - 2025)

Zevra Therapeutics (ZVRA) has disclosed Total Current Liabilities for 10 consecutive years, with $39.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Current Liabilities rose 15.3% year-over-year to $39.3 million, compared with a TTM value of $39.3 million through Dec 2025, up 15.3%, and an annual FY2025 reading of $39.3 million, up 15.3% over the prior year.
  • Total Current Liabilities was $39.3 million for Q4 2025 at Zevra Therapeutics, up from $26.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $73.7 million in Q4 2023 and bottomed at $2.9 million in Q1 2022.
  • Average Total Current Liabilities over 5 years is $21.6 million, with a median of $21.7 million recorded in 2023.
  • The sharpest move saw Total Current Liabilities plummeted 94.78% in 2021, then soared 513.16% in 2023.
  • Year by year, Total Current Liabilities stood at $4.2 million in 2021, then surged by 184.23% to $12.0 million in 2022, then skyrocketed by 513.16% to $73.7 million in 2023, then crashed by 53.79% to $34.1 million in 2024, then rose by 15.3% to $39.3 million in 2025.
  • Business Quant data shows Total Current Liabilities for ZVRA at $39.3 million in Q4 2025, $26.1 million in Q3 2025, and $28.8 million in Q2 2025.